YahooOctober 16, 2026 at 11:41 AM NY11 Days Ago
Novo Nordisk’s Growth Story Is Under Pressure as Eli Lilly Gains Ground
Novo Nordisk S/A (NYSE:NVO)’s investment story has changed dramatically. The stock has declined by over 25% since the start of 2026. The selloff has changed the stock’s valuation. Yahoo Finance’s latest data puts Novo Nordisk at 11.83 times forward earnings, compared with 13.33 in September 2025. That makes Novo look considerably less demanding than it […]
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
